Kenneth Alan Freedberg, M.D.
| Title | Professor in the Department of Health Policy and Management |
|---|
| Institution | Harvard School of Public Health |
|---|
| Department | Health Policy and Management |
|---|
| Address | Massachusetts General Hospital Div. of General Internal Medicine, 9th Floor 50 Staniford Street Boston MA 02114
|
|---|
| Phone | 617/724-3341 |
|---|
|
|
|
| Title | Professor of Medicine |
|---|
| Institution | Massachusetts General Hospital |
|---|
| Department | Medicine |
|---|
| Division | General Internal Medicine |
|---|
|
|---|
|
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Drain PK, Losina E, Parker G, Giddy J, Ross D, Katz JN, Coleman SM, Bogart LM, Freedberg KA, Walensky RP, Bassett IV. Risk Factors for Late-Stage HIV Disease Presentation at Initial HIV Diagnosis in Durban, South Africa. PLoS One. 2013; 8(1):e55305.
-
Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013 Jan 15; 158(2):84-92.
-
Robbins GK, Lester W, Johnson KL, Chang Y, Estey G, Surrao D, Zachary K, Lammert SM, Chueh HC, Meigs JB, Freedberg KA. Efficacy of a Clinical Decision-Support System in an HIV Practice: A Randomized Trial. Ann Intern Med. 2012 Dec 4; 157(11):757-66.
-
Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, Keatinge J, Park JE, Maruva M, Cerda R, Wood R, Dabis F, Freedberg KA. Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clin Infect Dis. 2013 Feb; 56(3):430-46.
-
Ahonkhai AA, Bassett IV, Ferris TG, Freedberg KA. Improving HIV outcomes in resource-limited countries: the importance of quality indicators. BMC Health Serv Res. 2012; 12:427.
-
Orrell C, Levison J, Ciaranello A, Bekker L, Kuritzkes D, Freedberg K, Wood R. Evolution of resistance in paediatric patients with failure on antiretroviral therapy. J Int AIDS Soc. 2012; 15(6):18086.
-
Ramirez-Avila L, Regan S, Giddy J, Chetty S, Ross D, Katz JN, Freedberg KA, Walensky RP, Losina E, Bassett IV. Depressive Symptoms and Their Impact on Health-seeking Behaviors in Newly-diagnosed HIV-infected Patients in Durban, South Africa. AIDS Behav. 2012 Nov; 16(8):2226-35.
-
Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, Walensky RP. The Clinical and Economic Impact of Genotype Testing at First-line Antiretroviral Therapy Failure for HIV-Infected Patients in South Africa. Clin Infect Dis. 2013 Feb; 56(4):587-97.
-
Kimmel AD, Resch SC, Anglaret X, Daniels N, Goldie SJ, Danel C, Wong AY, Freedberg KA, Weinstein MC. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost Eff Resour Alloc. 2012; 10(1):12.
-
Hom JK, Wang B, Chetty S, Giddy J, Mazibuko M, Allen J, Walensky RP, Losina E, Freedberg KA, Bassett IV. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. PLoS One. 2012; 7(8):e43281.
-
Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholié S, Freedberg KA. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2013; 18(1):45-55.
-
Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky RP. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012 Jun 1; 26(9):1083-93.
-
Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012 May 15; 26(8):987-95.
-
Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012; 7(4):e36001.
-
Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012 Jul; 55(2):279-90.
-
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD. The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. Clin Infect Dis. 2012 May; 54(10):1504-13.
-
Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012 Mar 13; 26(5):625-34.
-
Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, Freedberg KA, Wood R. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012; 7(3):e32144.
-
Ahonkhai AA, Noubary F, Munro A, Stark R, Wilke M, Freedberg KA, Wood R, Losina E. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012; 7(3):e32993.
-
Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis. 2012 Mar 1; 54(5):714-23.
-
Ciaranello AL, Perez F, Keatinge J, Park JE, Engelsmann B, Maruva M, Walensky RP, Dabis F, Chu J, Rusibamayila A, Mushavi A, Freedberg KA. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012 Jan; 9(1):e1001156.
-
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012 Jan 2; 26(1):45-56.
-
Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials. 2012 Jan-Feb; 13(1):1-10.
-
Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, Walensky RP, Freedberg KA, Losina E. Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir Immune Defic Syndr. 2012 Jan 1; 59(1):25-30.
-
Losina E, Freedberg KA. Life expectancy in HIV. BMJ. 2011; 343:d6015.
-
Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials. 2011 Sep-Oct; 12(5):277-85.
-
Linas BP, Wong AY, Freedberg KA, Horsburgh CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011 Sep 1; 184(5):590-601.
-
Messou E, Kouakou M, Gabillard D, Gouessé P, Koné M, Tchehy A, Losina E, Freedberg KA, Dri-Yoman TN, Anzian A, Toure S, Anglaret X. Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011 Jul 1; 57 Suppl 1:S34-9.
-
Ciaranello AL, Perez F, Maruva M, Chu J, Engelsmann B, Keatinge J, Walensky RP, Mushavi A, Mugwagwa R, Dabis F, Freedberg KA. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One. 2011; 6(6):e20224.
-
Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011; 9:59.
-
Lee PT, Kerry VB, Stone VE, Freedberg KA, Bangsberg DR. Transforming health professionals' education. Lancet. 2011 Apr 9; 377(9773):1235; author reply 1238-9.
-
Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):356-64.
-
Wang B, Losina E, Stark R, Munro A, Walensky RP, Wilke M, Martin D, Lu Z, Freedberg KA, Wood R. Loss to follow-up in a community clinic in South Africa--roles of gender, pregnancy and CD4 count. S Afr Med J. 2011 Apr; 101(4):253-7.
-
Chu J, Sloan CE, Freedberg KA, Yazdanpanah Y, Losina E. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. AIDS Res Ther. 2011; 8:14.
-
Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011 Feb 20; 25(4):479-92.
-
Hsu HE, Rydzak CE, Cotich KL, Wang B, Sax PE, Losina E, Freedberg KA, Goldie SJ, Lu Z, Walensky RP. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
-
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011 Jan; 56(1):26-35.
-
Bassett IV, Chetty S, Giddy J, Reddy S, Bishop K, Lu Z, Losina E, Freedberg KA, Walensky RP. Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med. 2011 Jan; 12(1):46-53.
-
Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther. 2011; 16(6):853-61.
-
Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010; 7(12):e1000382.
-
Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, Olender SA, Ostrowski M, Owen WF, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.
-
Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, Losina E, Freedberg KA, Danel C, Anglaret X, Yazdanpanah Y. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One. 2010; 5(10):e13414.
-
Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010 Oct 1; 51(7):823-9.
-
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010; 5(10):e13132.
-
Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, Stoler AW, Lu Z, Walensky RP, Flanigan TP, Bender MA, Freedberg KA, Swaminathan S. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010; 5(9).
-
Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B, Losina E, Freedberg KA, Weinstein MC, Goldie SJ. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010; 5(9).
-
Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials. 2010 Sep-Oct; 11(5):248-59.
-
Ivers LC, Chang Y, Gregory Jerome J, Freedberg KA. Food assistance is associated with improved body mass index, food security and attendance at clinic in an HIV program in central Haiti: a prospective observational cohort study. AIDS Res Ther. 2010; 7:33.
-
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010 Aug 15; 51(4):392-400.
-
Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis. 2010 Jul 1; 51(1):85-92.
-
Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, Messou E, Cotich KL, Walensky RP, Freedberg KA. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):258-68.
-
Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011 Jul; 18(7):506-12.
-
Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y. Economic evaluation of ART in resource-limited countries. Curr Opin HIV AIDS. 2010 May; 5(3):225-31.
-
Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, Ross D, Scott CA, Uhler LM, Katz JN, Holst H, Freedberg KA. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010; 5(3):e9538.
-
Williams-Roberts H, Chang Y, Losina E, Freedberg KA, Walensky RP. Frequent HIV testing among participants of a routine HIV testing program. Virulence. 2010 Mar-Apr; 1(2):68-71.
-
Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, Freedberg KA. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010 Mar 1; 50(5):779-86.
-
Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010 Feb 1; 50(3):416-25.
-
Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther. 2010; 15(3):351-61.
-
Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, Walensky RP, Freedberg KA, Losina E. Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS. 2010 Jan; 24 Suppl 1:S37-44.
-
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009 Nov 15; 49(10):1570-8.
-
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med. 2009 Oct; 6(10):e1000173.
-
Ivers LC, Cullen KA, Freedberg KA, Block S, Coates J, Webb P. HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis. 2009 Oct 1; 49(7):1096-102.
-
Brumme Z, Wang B, Nair K, Brumme C, de Pierres C, Reddy S, Julg B, Moodley E, Thobakgale C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C, Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u T, Losina E. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis. 2009 Sep 15; 49(6):956-64.
-
Linas BP, Losina E, Rockwell A, Walensky RP, Cranston K, Freedberg KA. Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5):513-21.
-
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009 Aug 4; 151(3):157-66.
-
April MD, Walensky RP, Chang Y, Pitt J, Freedberg KA, Losina E, Paltiel AD, Wood R. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr. 2009 Jul 1; 51(3):310-6.
-
Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, Lu Z, Losina E, Walensky RP, Freedberg KA. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009 Jun 1; 51(2):135-9.
-
Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009 Mar 15; 48(6):806-15.
-
Ciaranello AL, Walensky RP, Sax PE, Chang Y, Freedberg KA, Weissman JS. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials. 2009 Jan-Feb; 10(1):13-24.
-
Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14(4):523-31.
-
Ciaranello AL, Seage GR, Freedberg KA, Weinstein MC, Lockman S, Walensky RP. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS. 2008 Nov 12; 22(17):2359-69.
-
Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008 Oct 1; 22(15):2025-33.
-
Jean-Jacques M, Walensky RP, Aaronson WH, Chang Y, Freedberg KA. Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care. 2008 Sep; 20(8):977-83.
-
Bassett IV, Giddy J, Wang B, Lu Z, Losina E, Freedberg KA, Walensky RP. Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med. 2008 Nov; 9(10):863-7.
-
Walensky RP, Freedberg KA, Weinstein MC. Monitoring of antiretroviral therapy in low-resource settings. Lancet. 2008 Jul 26; 372(9635):288; author reply 289.
-
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis. 2008 May 1; 197(9):1324-32.
-
Ojikutu BO, Zheng H, Walensky RP, Lu Z, Losina E, Giddy J, Freedberg KA. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J. 2008 Mar; 98(3):204-8.
-
Valerio L, Yazdanpanah Y, Poizot-Martin I, Rosenthal E, Marimoutou C, Gastaut JA, Tran A, Dellamonica P, Freedberg KA, Pradier C. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2008 Jan 1; 47(1):50-5.
-
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007 Dec 15; 45 Suppl 4:S248-54.
-
Kumarasamy N, Venkatesh KK, Mayer KH, Freedberg K. Financial burden of health services for people with HIV/AIDS in India. Indian J Med Res. 2007 Dec; 126(6):509-17.
-
Wolf LL, Ricketts P, Freedberg KA, Williams-Roberts H, Hirschhorn LR, Allen-Ferdinand K, Rodriguez WR, Divi N, Wong MT, Losina E. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr. 2007 Dec 1; 46(4):463-71.
-
Ivers LC, Freedberg KA, Mukherjee JS. Provider-initiated HIV testing in rural Haiti: low rate of missed opportunities for diagnosis of HIV in a primary care clinic. AIDS Res Ther. 2007; 4:28.
-
Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
-
Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, Walensky RP. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007 Oct 1; 46(2):181-6.
-
Deuffic-Burban S, Losina E, Wang B, Gabillard D, Messou E, Divi N, Freedberg KA, Anglaret X, Yazdanpanah Y. Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling. Eur J Epidemiol. 2007; 22(10):737-44.
-
Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007 Oct 15; 45(8):1062-70.
-
Losina E, Figueroa P, Duncan J, Divi N, Wolf LL, Hirschhorn LR, Robertson M, Harvey K, Whorms S, Freedberg KA, Gebre Y. HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005. Int J Infect Dis. 2008 Mar; 12(2):132-8.
-
Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS. 2007 Jul; 21 Suppl 4:S117-28.
-
Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007 May 11; 21(8):973-82.
-
Holmes CB, Wood R, Maartens G, Freedberg KA, Losina E. Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa". J Acquir Immune Defic Syndr. 2007 Apr 1; 44(4):491.
-
Louis C, Ivers LC, Smith Fawzi MC, Freedberg KA, Castro A. Late presentation for HIV care in central Haiti: factors limiting access to care. AIDS Care. 2007 Apr; 19(4):487-91.
-
McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage GR. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007 Apr 15; 44(8):1115-22.
-
Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, Goldie SJ. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007 Mar; 120(3):272-9.
-
Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007 Jan 1; 44(1):30-7.
-
Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, Gabillard D, Seyler C, Freedberg KA, Anglaret X. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther. 2007; 12(4):543-51.
-
Losina E, Walensky RP, Geller A, Beddingfield FC, Wolf LL, Gilchrest BA, Freedberg KA. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007 Jan; 143(1):21-8.
-
Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006 Dec 5; 145(11):797-806.
-
Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Dec 1; 43 Suppl 1:S113-8.
-
Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR, Moore RD, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov; 44(11):990-7.
-
Liddicoat RV, Zheng H, Internicola J, Werner BG, Kazianis A, Golan Y, Rubinstein EP, Freedberg KA, Walensky RP. Implementing a routine, voluntary HIV testing program in a Massachusetts county prison. J Urban Health. 2006 Nov; 83(6):1127-31.
-
Linas BP, Zheng H, Losina E, Rockwell A, Walensky RP, Cranston K, Freedberg KA. Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis. 2006 Nov 15; 43(10):1357-64.
-
Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med. 2006 Sep 14; 355(11):1141-53.
-
Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006 Aug 1; 42(4):464-9.
-
Kimmel AD, Losina E, Freedberg KA, Goldie SJ. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ. 2006 Jul; 84(7):581-8.
-
Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J. 2006 Jun; 96(6):526-9.
-
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006 Jul 1; 194(1):11-9.
-
Holmes CB, Zheng H, Martinson NA, Freedberg KA, Walensky RP. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Clin Infect Dis. 2006 Jun 15; 42(12):1772-80.
-
Linas BP, Zheng H, Losina E, Walensky RP, Freedberg KA. Assessing the impact of federal HIV prevention spending on HIV testing and awareness. Am J Public Health. 2006 Jun; 96(6):1038-43.
-
Mrus JM, Schackman BR, Wu AW, Freedberg KA, Tsevat J, Yi MS, Zackin R. Variations in self-rated health among patients with HIV infection. Qual Life Res. 2006 Apr; 15(3):503-14.
-
Freedberg KA. The private side of the professional man. J Invest Dermatol. 2006 Mar; 126(3):533-5.
-
Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006 Mar-Apr; 7(2):59-69.
-
Liddicoat RV, Losina E, Kang M, Freedberg KA, Walensky RP. Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. AIDS Patient Care STDS. 2006 Feb; 20(2):84-92.
-
Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 1; 41(9):1316-23.
-
Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS. 2005 Aug 12; 19(12):1299-308.
-
Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 1; 39(1):69-77.
-
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making. 2005 May-Jun; 25(3):321-9.
-
Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar; 118(3):292-300.
-
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med. 2005 Feb 10; 352(6):586-95.
-
Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005; 10(1):41-52.
-
Samet JH, Horton NJ, Meli S, Dukes K, Tripps T, Sullivan L, Freedberg KA. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther. 2005; 10(1):83-93.
-
Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. Health Care Financ Rev. 2005; 26(4):67-80.
-
Walensky RP, Losina E, Malatesta L, Barton GE, O'Connor CA, Skolnik PR, Hall JM, McGuire JF, Freedberg KA. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005 Jan; 95(1):71-3.
-
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine. 2004 Sep 28; 22(29-30):4044-53.
-
Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004 Aug 1; 39(3):395-401.
-
Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES, Mallal SA, Goulder PJ, Brander C, Walker BD. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol. 2004 Jul; 78(13):7069-78.
-
Losina E, Islam R, Pollock AC, Sax PE, Freedberg KA, Walensky RP. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis. 2004 Jun 1; 38(11):1613-22.
-
Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004 Apr; 28(4):572-7.
-
Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses. 2004 Feb; 20(2):151-5.
-
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 1; 115(8):632-41.
-
Pincus JM, Crosby SS, Losina E, King ER, LaBelle C, Freedberg KA. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis. 2003 Dec 15; 37(12):1699-704.
-
Hanna GJ, Balaguera HU, Freedberg KA, Werner BG, Steger Craven KA, Craven DE, D'Aquila RT. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis. 2003 Oct 1; 188(7):986-91.
-
Hanslik T, Boëlle PY, Schwarzinger M, Carrat F, Freedberg KA, Valleron AJ, Flahault A. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine. 2003 Sep 8; 21(25-26):3614-22.
-
Mrus JM, Yi MS, Freedberg KA, Wu AW, Zackin R, Gorski H, Tsevat J. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making. 2003 Sep-Oct; 23(5):414-21.
-
Samet JH, Horton NJ, Traphagen ET, Lyon SM, Freedberg KA. Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res. 2003 May; 27(5):862-7.
-
Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Padmanabhan L, Stein MD. Discontinuation from HIV medical care: squandering treatment opportunities. J Health Care Poor Underserved. 2003 May; 14(2):244-55.
-
Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003 Mar 1; 36(5):652-62.
-
Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis. 2003 Jan 1; 36(1):86-96.
-
Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002 Dec 9-23; 162(22):2545-56.
-
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002 Dec; 7(4):257-66.
-
Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
-
Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 1; 31(1):27-37.
-
Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis. 2002 Sep 1; 35(5):606-10.
-
Seage GR, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. J Acquir Immune Defic Syndr. 2002 Aug 1; 30(4):421-8.
-
Johri M, David Paltiel A, Goldie SJ, Freedberg KA. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care. 2002 May; 40(5):429-41.
-
Wu AW, Jacobson KL, Frick KD, Clark R, Revicki DA, Freedberg KA, Scott-Lennox J, Feinberg J. Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res. 2002 May; 11(3):273-82.
-
Walensky RP, Losina E, Steger-Craven KA, Freedberg KA. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med. 2002 Apr 22; 162(8):887-92.
-
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002 Apr 22; 162(8):921-8.
-
Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002 Jan-Feb; 22(1):27-38.
-
Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001 Sep; 91(9):1456-63.
-
Bonds DE, Freedberg KA. Cost-effectiveness of prenatal screening for postpartum thyroiditis. J Womens Health Gend Based Med. 2001 Sep; 10(7):649-58.
-
Vidrih JA, Walensky RP, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med. 2001 Aug 15; 111(3):192-4.
-
Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001 Aug; 111(2):140-9.
-
Yazdanpanah Y, Chêne G, Losina E, Goldie SJ, Merchadou LD, Alfandari S, Seage GR, Sullivan L, Marimoutou C, Paltiel AD, Salamon R, Mouton Y, Freedberg KA. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001 Aug; 30(4):864-71.
-
Walensky RP, Rosenberg ES, Ferraro MJ, Losina E, Walker BD, Freedberg KA. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Infect Dis. 2001 Aug 15; 33(4):570-2.
-
Freedberg KA, Sullivan L, Georgakis A, Savetsky J, Stone V, Samet JH. Improving participation in HIV clinical trials: impact of a brief intervention. HIV Clin Trials. 2001 May-Jun; 2(3):205-12.
-
Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001 Mar 20; 134(6):440-50.
-
Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001 Mar 15; 344(11):824-31.
-
Paltiel AD, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001 Mar 1; 32(5):783-93.
-
Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS. 2001 Jan 5; 15(1):77-85.
-
Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000 Jun 1; 108(8):634-41.
-
Kaplan JE, Masur H, Holmes KK, Freedberg KA, Holtgrave D, Piscitelli SC, Van Dyke R, Watts H. An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Infect Dis. 2000 Apr; 30 Suppl 1:S15-28.
-
Gross PA, Asch S, Kitahata MM, Freedberg KA, Barr D, Melnick DA, Bozzette SA, Bozette SA. Performance measures for guidelines on preventing opportunistic infections in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000 Apr; 30 Suppl 1:S85-93.
-
Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: A cost-effectiveness analysis. J Am Acad Dermatol. 1999 Nov; 41(5 Pt 1):738-45.
-
Yazdanpanah Y, Goldie SJ, Salamon R, Mouton Y, Freedberg KA. Are European-specific guidelines needed for prevention of opportunistic infections in HIV-1? Lancet. 1999 Oct 9; 354(9186):1305-6.
-
Freedberg KA, Samet JH. Think HIV: why physicians should lower their threshold for HIV testing. Arch Intern Med. 1999 Sep 27; 159(17):1994-2000.
-
Marine JE, Freedberg KA, Davidoff R. Cost-effectiveness of stress-echocardiography. Cardiol Clin. 1999 Aug; 17(3):583-95, x.
-
Samet JH, Muz P, Cabral P, Jhamb K, Suwanchinda A, Freedberg KA. Dermatologic manifestations in HIV-infected patients: a primary care perspective. Mayo Clin Proc. 1999 Jul; 74(7):658-60.
-
Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999 May 19; 281(19):1822-9.
-
Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med. 1999 Jan 19; 130(2):97-107.
-
Scharfstein JA, Paltiel AD, Weinstein MC, Seage GR, Losina E, Craven DE, Freedberg KA. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Int J Technol Assess Health Care. 1999; 15(3):531-47.
-
Freedberg KA, Paltiel AD. Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. Pharmacoeconomics. 1998 Aug; 14(2):165-74.
-
Samet JH, Freedberg KA, Stein MD, Lewis R, Savetsky J, Sullivan L, Levenson SM, Hingson R. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med. 1998 Apr 13; 158(7):734-40.
-
Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998 Apr-Jun; 18(2 Suppl):S93-105.
-
Stein MD, Freedberg KA, Sullivan LM, Savetsky J, Levenson SM, Hingson R, Samet JH. Sexual ethics. Disclosure of HIV-positive status to partners. Arch Intern Med. 1998 Feb 9; 158(3):253-7.
-
Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998 Jan 14; 279(2):130-6.
-
Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making. 1997 Oct-Dec; 17(4):373-81.
-
Freedberg KA, Cohen CJ, Barber TW. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1; 15(4):275-82.
-
Freedberg KA, Hardy WD, Holzman RS, Tosteson AN, Craven DE. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making. 1996 Jan-Mar; 16(1):29-35.
-
Kaplan JE, Masur H, Holmes KK, Wilfert CM, Sperling R, Baker SA, Trapnell CB, Freedberg KA, Cotton D, Powderly WG, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis. 1995 Aug; 21 Suppl 1:S12-31.
-
Samet JH, Libman H, LaBelle C, Steger K, Lewis R, Craven DE, Freedberg KA. A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Arch Intern Med. 1995 Aug 7-21; 155(15):1629-33.
-
Lebow JM, O'Connell JJ, Oddleifson S, Gallagher KM, Seage GR, Freedberg KA. AIDS among the homeless of Boston: a cohort study. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1; 8(3):292-6.
-
Bergquist SR, Felson DT, Prashker MJ, Freedberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1995 Mar; 38(3):326-33.
-
Freedberg KA. Clinical and economic aspects of prophylaxis and treatment of Pneumocystis carinii pneumonia. Pharmacoeconomics. 1995 Feb; 7(2):95-8.
-
Glotzer DE, Freedberg KA, Bauchner H. Management of childhood lead poisoning: clinical impact and cost-effectiveness. Med Decis Making. 1995 Jan-Mar; 15(1):13-24.
-
Orlander JD, Samet JH, Kazis L, Freedberg KA, Libman H. Improving medical residents' attitudes toward HIV-infected persons through training in an HIV staging and triage clinic. Acad Med. 1994 Dec; 69(12):1001-3.
-
Freedberg KA, Malabanan A, Samet JH, Libman H. Initial assessment of patients infected with human immunodeficiency virus: the yield and cost of laboratory testing. J Acquir Immune Defic Syndr. 1994 Nov; 7(11):1134-40.
-
Samet JH, Retondo MJ, Freedberg KA, Stein MD, Heeren T, Libman H. Factors associated with initiation of primary medical care for HIV-infected persons. Am J Med. 1994 Oct; 97(4):347-53.
-
Glotzer DE, Bauchner H, Freedberg KA, Palfrey S. Screening for childhood lead poisoning: a cost-minimization analysis. Am J Public Health. 1994 Jan; 84(1):110-2.
-
Freedberg KA, Tosteson AN, Cotton DJ, Goldman L. Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis. J Gen Intern Med. 1992 May-Jun; 7(3):261-72.
-
Freedberg KA, Tosteson AN, Cohen CJ, Cotton DJ. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991; 4(5):521-31.
-
Freedberg KA, Innis RB, Creese I, Snyder SH. Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci. 1979 Jun 25; 24(26):2467-73.
This graph shows the total number of publications by year.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Maria Maxell (mmaxellhsph.harvard.edu). HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
|
Freedberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|